EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Core Insights - EyePoint Pharmaceuticals, Inc. has granted non-statutory stock options to new employees as inducement awards outside the 2023 Long-Term Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4) [1][2] Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases [3] - The company's lead product candidate, DURAVYU™, is an investigational treatment for VEGF-mediated retinal diseases, currently in Phase 3 global clinical trials for wet age-related macular degeneration (wet AMD) and has recently completed a Phase 2 trial for diabetic macular edema (DME) [3][5] - EyePoint utilizes its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery, which has been safely administered in multiple FDA-approved products [4] Stock Option Details - The company granted stock options to purchase a total of 12,500 shares of common stock to three new employees, with an exercise price of $9.03 per share, the closing price on June 13, 2025 [2] - The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the next three years, contingent on continued service [2]